Leveraging Genetics for Hereditary Angioedema: A Road Map to Precision Medicine
- 28 January 2021
- journal article
- review article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 60 (3) , 416-428
Abstract
Biochemical studies performed during the last decades resulted in the development of various innovative medicinal products for hereditary angioedema (HAE). These therapeutic agents target the production or the function of bradykinin—the main mediator of HAE due to C1-inhibitor (C1-INH) deficiency. However, despite these remarkable achievements, current knowledge cannot provide convincing explanations for the clinical variability of the disease. As a consequence, treatment indications apply for drugs available for C1-INH deficiency. The advent of high-throughput next-generation sequencing technologies may assist in covering the missing part of our understanding of HAE pathogenesis. During the last 3 years alone, several new entities were added to the already described genotypes. The recent discovery of four novel target genes expands our understanding of other causes which may explain recurrent angioedema in individuals and families with normal C1-INH activity. Furthermore, new genetic technologies allowed the recognition of deep intronic variants associated with the disease, and elegant functional studies characterized new variants for the C1-INH gene. Thus, evidence has been provided regarding pathogenetic aspects remaining obscure for many years, such as the defective intracellular transport of mutant C1-INH, and environmental effect on the disease expression. Therefore, it seems that the stage for Precision Medicine era in HAE management is ready. Disease endotypes are expected to be uncovered and specified targets for therapeutic intervention will be detected, promising a more effective, individualized management of the disease.Keywords
This publication has 116 references indexed in Scilit:
- De novo homozygous mutation of the C1 inhibitor gene in a patient with hereditary angioedemaJournal of Allergy and Clinical Immunology, 2013
- Hereditary Angioedema Nationwide Study in Slovenia Reveals Four Novel Mutations in SERPING1 GenePLOS ONE, 2013
- Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedemaPharmacogenetics and Genomics, 2010
- Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With HypertensionThe Journal of Clinical Hypertension, 2010
- Obstetrical Complications and Outcome in Two Families with Hereditary Angioedema due to Mutation in the F12 GeneObstetrics and Gynecology International, 2010
- Bradykinin Type 2 Receptor BE1 Genotype Influences Bradykinin-Dependent Vasodilation During Angiotensin-Converting Enzyme InhibitionHypertension, 2008
- Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type IIIThe American Journal of Human Genetics, 2006
- Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitorBiochemical and Biophysical Research Communications, 2006
- Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedemaJournal of Allergy and Clinical Immunology, 2000
- Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.Journal of Clinical Investigation, 1995